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Abstract: Photoaffinity labeling is a powerful technique for identifying a target protein. A 
high degree of labeling specificity can be achieved with this method in comparison to 
chemical labeling. Human serum albumin (HSA) and α1-acid glycoprotein (AGP) are two 
plasma proteins that bind a variety of endogenous and exogenous substances. The ligand 
binding mechanism of these two proteins is complex. Fatty acids, which are known to be 
transported in plasma by HSA, cause conformational changes and participate in allosteric 
ligand binding to HSA. HSA undergoes an N-B transition, a conformational change at 
alkaline pH, that has been reported to result in increased ligand binding. Attempts have 
been made to investigate the impact of fatty acids and the N-B transition on ligand binding 
in HSA using ketoprofen and flunitrazepam as photolabeling agents. Meanwhile, plasma 
AGP is a mixture of genetic variants of the protein. The photolabeling of AGP with 
flunitrazepam has been utilized to shed light on the topology of the protein ligand binding 
site. Furthermore, a review of photoaffinity labeling performed on other major plasma 
proteins will also be discussed. Using a photoreactive natural ligand as a photolabeling 
agent to identify target protein in the plasma would reduce non-specific labeling. 
Keywords: photoaffinity labeling; plasma proteins; human serum albumin; α1-acid 
glycoprotein; photoreactivity; protein binding; labeling specificity 
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Identification of target proteins is pivotal in drug discovery, and elucidation of the ligand binding 
site topology on the target protein is critical for drug development. Photoaffinity labeling is a useful 
and reliable method to identify the binding protein in complex mixtures of biological molecules such 
as those found in the cytosol or the plasma. Through this method, structural information on the ligand 
binding site can be obtained by identifying the amino acid residues that are located at these sites. Thus, 
photoaffinity labeling is a powerful tool that is applicable in both drug discovery and development 
processes [1]. 
Different from chemical labelling, photoaffinity labeling enables formation of a covalent bond 
between a ligand and its specific binding protein at will. (Figure 1) The technique requires a 
chemically inert ligand to be converted into a highly reactive intermediate by irradiation with near 
ultraviolet or visible lights after its binding to a protein is complete. This will allow important 
preliminary experiments of a photoaffinity labeling agent such as binding affinity measurements and 
assays of biological activities to be performed with ease [2]. Covalent adduct formation can be 
confined to the desired site, thereby further reduce non-specific labeling, by removing the unbound 
photolabeling reagents after incubation and rapidly irradiate the ligand-protein complex before 
dissociation takes place. 
Figure 1. Photoaffinity labeling (A) and chemical affinity labeling (B). 
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The photogenerated species are usually so reactive that they can react with carbon-hydrogen bonds. 
This precludes the need for the presence of a particular functional group at the binding site of the 
protein for the photogenerated intermediates to react and form a covalent bond with. In contrast, 
functional group-specific reagents may be essential in a chemical affinity labeling experiment in order 
to form a covalent bond with a specific functional group that is present at the protein binding site. 
Extreme conditions that are detrimental to the proteins such as extreme pH values, high temperatures 
or pre-reduction of disulfide bonds may be required for efficient reaction of a chemical labeling 
reagent. Misleading results can be obtained when attempts are made to chemically label an inert 
binding site lacking of the required functional group. Furthermore, keeping the non-specific labeling at 
an acceptable low level is a constant challenge in chemical labeling experiments [3]. 
The major drawbacks of photoaffinity labeling experiments is the photooxidative damage to 
proteins at short wavelengths due to the direct reaction of excited chromophores such as tryptophan in 
the protein with oxygen, or because of the generation of oxygen radicals by the photolabeling agent in 
the sample. Some photolabeling agents may cause problems at wavelengths in the visible region. 
Photooxidative damages include crosslinking of proteins and the loss of binding capacity of proteins 
for ligands. One way of overcoming this problem is to pass a stream of water-saturated nitrogen or 
argon to remove dissolved oxygen in order to reduce the level of such photooxidative damage [3]. 
Photoaffinity labeling can be a powerful technique for studying the properties and functions of a 
protein. Figure 2 summarizes a scheme of a typical photoaffinity labeling experimental protocol for 
identification of the ligand binding site amino acid sequence. A direct link can then be made by  
site-directed mutagenesis of the amino acid residues that were previously identified by photoaffinity 
labeling. Depending on the nature of the mutation, various functional changes including ligand binding 
properties may take place, which can be reconfirmed by photoaffinity labeling of the mutants. 
Identifying amino acid residues for which mutations alter the functional properties of the biological 
protein allow structure function relationships to be evaluated and interpreted. 
2. Plasma Proteins 
Plasma proteins comprise a variety of proteins that can be classified according to their known  
roles and functions. They include immunoglobulins, hormones, cytokines, blood coagulation and 
fibrinolysis, complements, enzymes, lipoproteins, transport and storage proteins, and other proteins [4]. 
Human serum albumin (HSA) belongs to the class of transport and storage proteins whereas  
α1-acid glycoprotein (AGP) is classified under immune systems, since it is an acute phase protein. 
They are two major plasma proteins that are known to bind a broad spectrum of drugs, in addition to 
their extraordinary binding capacity for endogenous substances [5]. There are proteins of other classes 
that also interact with a great variety of yet to be identified endogenous as well as exogenous 
substances. In addition to understanding the physiological role and function of each of these plasma 
proteins, knowledge of the range of their interacting ligands will certainly foster and enhance drug 
discovery and development processes.  
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Figure 2. A typical photoaffinity labeling experimental protocol to identify the ligand 
binding site of a target protein (A), starting from synthesizing the photolabeling agent by 
linking the ligand with a suitable photoreactive moiety (B). Photolabeling the protein in the 
presence of excess parent ligand (C) would allow identification of the binding site peptide 
from the non-specifically labeled peptides of the protein after chemical cleavage or 
enzymatic digestion (D) [2,3,6]. 
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2.1. Human Serum Albumin 
HSA is the most abundant protein in plasma that is responsible for maintaining the oncotic pressure 
of blood vessels. (Figure 3) It is also a major carrier of a broad spectrum of endogenous substances 
such as long chain fatty acids, bilirubin and thyroid hormones. HSA has two major and distinct sites 
for the high-affinity binding of several physiologically important compounds and a large number of 
drugs, namely site I and site II [7,8]. Crystallographic investigations found that drug binding sites I and 
II are located in subdomains IIA and IIIA respectively [9]. Ligands that interact with site I include 
thyroxine, bilirubin, warfarin whereas diazepam, octanoic acid, arylpropionic acids such as ketoprofen 
(KP) and ibuprofen primarily bind to site II. 
Figure 3. Crystal structures of the human serum albumin. The illustration was produced by 
PyMol using the atomic coordinates from Protein Data Bank, PDB2BXA [9]. 
 
2.1.1. Ketoprofen 
KP has a photoreactive benzophenone moiety in its chemical structure [10], hence it can be used as 
a photoaffinity labeling reagent without further structural modification. Cyanogen bromide cleavage of 
the HSA photolabeled with [14C]KP revealed that 11.6 kDa and 9.4 kDa fragments, corresponding to 
domain III and subdomain IA respectively, contain most of the photoincorporated radioactivity. 
(Figure 4A) Competition experiments using other site II ligands, diazepam (DZP) and octanoic acid, 
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inhibited the photobinding of [14C]KP to the 11.6 kDa fragment, suggesting that this fragment contains 
the common binding region for site II ligands [11]. Further photolabeling studies with [14C]KP on 
native and recombinant mutants albumins, R410C and R485A confirmed the importance of R410 in 
the high affinity binding of arylpropionic acid derivatives possibly through electrostatic interaction, 
whilst R485 contributed to the binding in the form of non-electrostatic interaction with the 
benzophenone moiety of KP since R485 was found to form a covalent adduct with KP [12]. 
Figure 4. Crystal structures of HSA showing the locations of methionine residues (A), 
histidine146 and the binding sites of myristates (B). The 9.4 kDa (subdomain IA) and  
11.6 kDa (subdomain IIIA) CNBr fragments photolabeled by [14C]KP were shown in green 
and cyan respectively. Both illustrations were produced by PyMol using the atomic 
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Long chain fatty acids are insoluble in water and are carried in the plasma either in the form of 
esterified triacylglycerols carried by lipoproteins, or in a non-esterified form bound to albumin. The 
plasma concentration of HSA is around 0.6 mM and the molecule can carry at least six molecules of 
fatty acids. Under normal physiological conditions, HSA carries approximately 0.1–2 moles of fatty 
acids per mole of protein. No significant increase in the free fraction of KP was observed when an 
ultrafiltration binding experiment was performed in the presence of up to a myristate (MYR):HSA 
ratio of 3. Based on the results of ultrafiltration experiments, it is reasonable to conclude that the first 
three molecules of MYR bind to a different region than subdomain III. Photolabeling of HSA with 
[14C]KP in the presence of MYR at increasing MYR:HSA ratios of 1 to 3 showed a decrease in 
[14C]KP covalent binding to subdomain III but an increase in the binding to subdomain IA. The results 
of photoaffinity labeling revealed that a concurrent competitive and allosteric binding mechanism by 
MYR up until a MYR:HSA ratio of 3 is operative, which mainly involves domain I as the site for 
allosteric binding of the displaced [14C]KP. This illustrates the usefulness of the photoaffinity labeling 
technique in examining the complex binding behavior of HSA especially when long-chain fatty acids 
are involved (Figure 4B) [13]. 
HSA undergoes a conformational change at different pH values, which appears to have an impact 
on its ligand binding properties [5,14]. Yamasaki et al. reported that when HSA undergoes a 
conformational change from the neutral (N) to the base (B) conformation (the N-B transition) in the 
physiological pH region, a “competitive”-like strong allosteric regulation exists that affects both of the 
major binding, sites I and II, of HSA [15]. The results of ultrafiltration binding experiments reported 
by Kaneko et al. performed at increasing pH of 6.5, 7.4 and 8.2 indicated an increase in the percentage 
binding of KP to HSA with increasing pH. Interestingly, the results of photoaffinity labeling studies 
performed at similar pH conditions showed a comparable extent of covalent binding of [14C]KP to 
domain III but there was an increase in the covalent binding of [14C]KP to subdomain IA was observed 
with increasing pH [16]. In a previous study, Kosa et al. proposed that histidine residues located in 
domain I were responsible for the N-B transition [17]. In a point mutation study, Yang et al. confirmed 
that H9, H67, H105, H128 and H146 are significant contributors to the N-B transition via electrostatic 
interactions [18]. In an attempt to examine the role of histidines in N-B transition induced ligand 
binding change, Kaneko et al. photolabeled six histidine single mutants of HSA, namely, H9A, H39A, 
H67A, H105A, H128A and H146A, with [14C]KP at pH 6.5, 7.4 and 8.2 and concluded that H146 
plays a prominent role in the allosteric binding induced by N-B transition [16]. 
2.1.2. Flunitrazepam 
Site II of HSA, also known as the indole-benzodiazepine (BDZ) site, is a primary binding site for 
DZP and other BDZ drugs. However, differences in the binding characteristics of BDZ drugs that 
contain an asymmetric center as well as the type of moiety at position 7 have been reported.  
Noctor et al. reported the existence of a very low affinity nitro-BDZ site, or sites that may be different 
from site II [19,20]. Flunitrazepam (FNZP) is a BDZ with a nitro group at position 7 that did not 
displace the site II fluorescent probe, dansylsarcosine, to an extent similar to that of DZP. FNZP has 
been used as a photolabeling agent in BDZ-receptor studies [21]. The photolabeling profiles of HSA 
with [3H]FNZP in the presence of site I and site II ligands, including DZP, indicated that these ligands 
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did not inhibit the covalent binding of [3H]FNZP to HSA. In contrast, DZP inhibited the covalent 
binding of [3H]FNZP to AGP. These results suggest that subdomain III A of HSA does not function as 
a binding site for FNZP [22]. 
2.1.3. Halothane 
In an attempt to investigate the interaction of volatile anesthetics and proteins, Eckenhoff et al. 
photolabeled bovine serum albumin (BSA) with [14C]halothane in the presence and absence of  
other volatile anaesthetics by exposing the mixture to 254 nm UV light for 10 s. Chloroform, 
methoxyflurane, isoflurane, diethyl ether, ethanol, oleate and low pH inhibited photoincorporation of 
[14C]halothane to BSA [23]. In a subsequent photolabeling experiment to determine the binding site 
amino acid sequence, BSA was found to have a higher affinity for [14C]halothane than HSA. The 
major photolabeled site of [14C]halothane was in subdomain IIA involving tryptophan residue for both 
BSA and HSA [24]. Two molecules of halothane were found to bind at the interface between 
subdomains IIA and IIB, in close proximity with tryptophan 214, which can also bind a fatty acid 
molecule in an X-ray crystallographic study conducted by Battacharya et al. [25]. 
2.1.4. Leukotriene  
Albumin has been reported having a stabilising effect on leukotriene A4 that is reversed by warfarin 
which binds to subdomain IIA (site I) [26]. On the other hand, leukotriene B4 has been reported to 
bind to subdomain IIIA (site II) [27]. Falk et al. showed that albumin was labelled when rat as well as 
human serum was subjected to direct photoaffinity labeling in the frozen state after cryofixation using 
[3H8]leukotriene E4, followed by irradiation at 300 nm. Cryofixation eliminates the unspecific labeling 
by photoisomers and photodegradation products of leukotrienes [28]. However, no attempt has been 
made to characterise the binding site of leukotriene E4 on the albumins. 
2.2. α1-Acid Glycoprotein 
α1-Acid glycoprotein (AGP), or orosomucoid, is a member of the lipocalin family. It is classified as 
an acute phase protein, since its serum concentration increases from 2- to a 10-fold in response to 
various pathophysiological conditions such as a systemic tissue injury, an inflammation or an infection. 
AGP is a single chain glycoprotein with a molecular weight of 41–43 kDa and contains 183 amino acid 
residues with two disulfide bridges. It is heavily glycosylated, with a carbohydrate content that 
accounts for 45% of the molecular weight, and it is negatively charged, with a pI of 2.8–3.8 due to the 
presence of sialic acid residues. Five highly sialylated complex-type-N-linked glycans are attached to 
asparagine residues 15, 38, 54, 75 and 85. The microheterogeneity of AGP’s glycosylation can be 
modified and change depending on the type of systemic inflammation or disease. In addition, plasma 
AGP is a mixture of genetic variants, consisting of at least two genetic variants, namely, F1*S  
(Figure 5A) and A variants (Figure 5B), the relative proportions of which change during an acute 
phase reaction such as inflammation. The appearance of different glycosylation patterns of AGP can 
influence its immunomodulatory and ligand binding properties. AGP binds numerous basic and neutral 
lipophilic drugs as well as endogenous steroid hormones such as progesterone. AGP can also bind 
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acidic drugs such as phenobarbital [29–36]. Each genetic variant of AGP has a different ligand binding 
specificity that contributes to the complexity of ligand binding to AGP [37]. 
Figure 5. Crystal structures of the human AGP F1*S (A) and A variants (B). Both 
illustrations were produced by PyMol using the atomic coordinates from the Protein Data 
Bank, 3KQ0 for (A) [37] and 3APX for (B). 
(A) F1*S variant (B) A variant 
2.2.1. Flunitrazepam 
Further investigations of the binding site of FNZP in AGP through photoaffinity labeling revealed 
that sialic acid is not involved in the binding and that FNZP is a common ligand between the F1*S 
variants and A variant. The photolabeled peptide corresponded to Tyr91-Arg105 of AGP [38].  
In addition to FNZP, clonazepam has been reported to be a photoaffinity labeling agent by  
Sieghart et al. [39]. 
2.2.2. 7-Hydroxystaurosporine (UCN-01) 
7-Hydroxystaurosporine (UCN-01) is a protein kinase inhibitor anticancer drug that exhibits an 
extraordinary high binding affinity for AGP involving tryptophan residues of AGP. Like FNZP, no 
significant difference was found for the binding of UCN-01 to F1*S and A variants of AGP [40]. The 
photolabeling of AGP with UCN-01 indicated that Trp-160 formed a covalent adduct with the drug. 
This result was confirmed by the finding that only the mutant W160A of AGP showed a marked 
decrease in the extent of photoincorporation in another photolabeling study on three recombinant AGP 
mutants (W25A, W122A, and W160A) [41]. 
  




Turk et al. synthesized a photoactive thalidomide derivative as a probe to elucidate the molecular 
mechanism for the immunomodulatory effect of thalidomide, which has been attributed to the selective 
inhibition of tumor necrosis factor alpha from monocytes. A pair of proteins of 43–45 kDa with a high 
acidity from bovine thymus extract were photolabeled with the photoactive thalidomide derivative  
and found to be AGP. A subsequent photolabeling study of human AGP revealed that thalidomide 
inhibited the covalent binding at therapeutic concentrations for inhibition of tumor necrosis  
factor alpha production from human monocytes, suggesting that AGP may be involved in the 
immunomodulatory activity of thalidomide [42]. 
2.3. Thyroxine-Binding Prealbumin (Transthyretin) 
Thyroxine-binding prealbumin (transthyretin, TTR) is a protein located in the “prealbumin” zone 
upon an electrophoretic analysis of plasma proteins. (Figure 6) It is synthesized in the liver, choroids 
plexus in the brain, and the eye. Its binding affinity for thyroxine is less than that of thyroxine-binding 
globulin but greater than that of albumin. It also transports retinol via binding to the retinol-binding 
protein, hence the name trans(port)-thy(roxine)-retin(ol). TTR exists in homotetramer that complexes 
with the retinol-binding protein in a molar ratio of 1:1 in plasma. TTR has a dimer configuration with a 
central channel containing two high-affinity binding sites for thyroid hormones. Anthranilic acid 
derivatives, such as flufenamic, meclofenamic, and mefenamic acids, have also been found to interact 
strongly with TTR [43]. The highly conserved structure of TTR has been shown to be associated  
with the pathogenesis of Alzheimer’s disease, depression, and lead toxicity. Since TTR is a highly 
amyloidogenic protein because it contains a β-sheet structure, it becomes a precursor protein in 
familial amyloidotic polyneuropathy. Moreover, TTR plays important roles in various central nervous 
system disorders, diabetes mellitus, and lipid metabolism [44,45]. 
Figure 6. Crystal structures of the human transthyretin. The illustration was produced by 
PyMol using the atomic coordinates from the Protein Data Bank, PDB1DVQ [46]. 
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2.3.1. [3'5'-125I]-Thyroxine and Triiodothyronine 
Dozin et al. reported that irradiation with light above 300 nm photolabeled [3',5'-125I]thyroxine (T4) 
or [3'-125I]triiodothyronine (T3) to human thyroxine binding globulin and BSA [47]. Van der Walt et al. 
reported that the irradiation of T4 and 3,5,3'-T3 with near UV (wavelengths greater than 300 nm) for 
30 min and 18 h resulted in the covalent binding to albumin and TTR respectively. The mechanism of 
labelling was proposed to be due to homolytic fission of C-I bonds, which results in the generation of 
phenyl radicals, and possibly also to iodine radicals. The absence of aromatic residues at the binding 
site of TTR as well as the low degree of freedom of movement of T4 within the binding site 
contributed to the slow covalent bond formation with TTR [48]. On the other hand, Somack et al. 
demonstrated that the photoirradiation of TTR at 254 nm for a much shorter length of time, 15 s,  
with [125I]-L-T4 also led to covalent bond formation, and the same extent of photolabeling could be 
achieved after 25 min of irradiation with a 350 nm light source. It is noteworthy that since the T4 used 
in the two studies were radiolabeled with 125I exclusively in the outer ring 3’ and 5’ positions, if some 
of the covalent bond formation involved the photoinduced loss of these iodines, then the specific 
radioactivity of the covalently bound ligand would be reduced thus leading to an underestimation of 
the extent of photoattachment. This might be the reason for the increase in the amount of covalently 
bound radioactivity to HSA from 25% to 46% when the phenolic ring-labeled [3’,5’-125I]T4 was 
replaced with side chain-labeled [2-14C]T4 reported by van der Walt [48]. 
2.3.2. Thyroxine Derivatives 
125I-Labeled 3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-dinitrophenyl]-propionic acid has been 
shown to be able to form covalent attachment to TTR upon photoirradiation at 317 nm for 1 h [49]. On 
the other hand, Somack et al. synthesized N-(ethyl-2-diazomalonyl)-3,5,3'-triiodothyronine (EDM-T3) 
and N-(ethyl-2-diazomalonyl)thyroxine (EDM-guT4) as thyroid hormone analogues to photolabel TTR, 
T4 binding globulin, and albumin in unfractionated human serum. The photolysis of [125I]-L-EDM-T4 
and TTR mixture at 254 nm resulted in the covalent binding of [125I]-L-EDM-T4 to TTR. The 
mechanism of covalent photoattachment was proposed to occur via a carbene-dependent pathway 
derived from the photolysis of the diazo group, and a carbene-independent pathway that may involve 
attachment via radical formation following the photoinduced loss of the thyronine ring iodine. The 
efficiency of photoattachment of [125I]-L-EDM-T4 to TTR was concluded to be higher than L-T4 [50]. 
2.4. Plasma Retinol-Binding Protein 
Plasma retinol-binding protein (RBP) is a member of the lipocalin family that specifically carries 
all-trans-retinol in the blood, delivering retinol to peripheral tissues from stores in the liver. (Figure 7) 
RBP itself is bound to TTR in a 1 to 1 stoichiometry when circulating in the plasma. In vitro, one 
tetramer of TTR can bind two molecules of retinol-binding protein. (Figure 8) [51]. The TTR and RBP 
complex is an absolute requirement for retinol binding, but a RBP containing retinoic acid does not 
form complex with TTR [52]. This protein-protein complexation between the RBP and TTR prevents 
RBP from being filtered and loss via kidney glomeruli. Within the cell, the all-trans-retinol molecule, 
as well as its oxidized form all-trans-retinal, is bound to one of the two isoforms of cellular  
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retinol-binding proteins (CRBP I and CRBP II), while the oxidized form of all-trans-retinal,  
all-trans-retinoic acid binds to one of the two cellular retinoic acid binding protein isoforms  
(CRABP I and CRABP II) [53]. 
Figure 7. Crystal structures of the human plasma retinol binding protein. The illustration 
was produced by PyMol using the atomic coordinates from the Protein Data Bank, 
PDB1JYD [54]. 
 
Figure 8. Crystal structures of the hexameric complex of human retinol-binding protein 
(RBP) with its carrier protein transthyretin. The RBP molecules are shown in salmon red, 
one of the TTR dimers is in green and yellow, and the other is in blue and magenta. The 
retinol molecules are represented as space-filling models with white carbon atoms and a 
hotpink oxygen. The illustration was produced by PyMol using the atomic coordinates 
from the Protein Data Bank, PDB 1QAB [55]. 
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2.4.1. All-Trans-Retinoic Acid and Azidoretinoids 
Retinoic acid can be used as a photoaffinity probe without further modification due to the fact that it 
contains an α,β-unsaturated carbonyl group and has a highly conjugated polyene structure. After 
exposure of the radioactively labeled all-trans-retinoic acid in complex mixtures of cytosolic proteins 
to an intense 365 nm UV light for 15 min, two known retinoic acid-binding proteins, CRBP and 
albumin, were labelled specifically [56]. Direct photoaffinity labeling of cellular retinoic acid-binding 
protein I with all-trans-retinoic acid identified Trp7, Lys20, Arg29, Lys38, and Trp109 to be the amino 
acids that have been modified [57]. On the other hand, C(5)-azido-substituted aromatic retinoids have 
also been shown to be effective as photoaffinity probes as the substituted retinoids retain their 
biological activity and affinity for CRBP [58]. 
Recently, RBP has been reported to have a role in adiposity, insulin resistance, and type 2  
diabetes [59–62]. It would be interesting to further analyse these newly discovered functional roles of 
RBP by photoaffinity labelling technique. There has not been any report on photolabeling RBP, but 
retinoic acid should be a useful probe for this purpose since RBP binds retinoic acid at similar affinity 
as retinol [51,63]. A retinol azido-derivative, 4-azidoretinol, has been reported to be displaced by  
all-trans-retinol in labelling CRBP from liver, which should also be applicable to photolabel RBP [64]. 
2.5. Vitamin D-Binding Protein (Gc-Globulin) 
Vitamin D (cholecalciferol) is carried in the bloodstream to the liver, where it is hydroxylated  
by the microsomal enzyme vitamin D 25-hydroxylase to form 25-hydroxycholecalciferol (calcidiol). 
(Figure 9) Circulating calcidiol is then released into the plasma, where it binds to an α-globulin, 
vitamin D binding protein (VDBP). The resulting 25(OH)D3 is the major circulating form of vitamin D. 
It is then transported to the proximal tubules of the kidneys, where it is hydroxylated again at either  
the 1-α or the C24 position to form calcitriol (1,25-dihydroxycholecalciferol, 1α,25(OH)2D) or 
24R25(OH)2D3. Calcitriol, which is the physiologically active form of vitamin D, is released into the 
circulation and transported to various target organs by binding to VDBP [65]. 
VDBP is a member of the albumin gene family, and a multifunctional single chain plasma protein 
that is predominantly synthesized in liver with structural and functional properties similar with serum 
albumin, afamin and α-fetoprotein. It is found in plasma, ascitic fluid, cerebrospinal fluid and on the 
surface of many cell types. It binds to vitamin D and its plasma metabolites and transports them to 
target tissues and transports fatty acids as well as monomeric actin. VDBP has been shown to play a 
role in the systemic control of osteoclastic bone resorption, and behave as a co-chemotaxin specific for 
the complement peptide C5a. Its galactose or sialic acid-free form has been reported to be potent 
macrophage-activating factors [66,67]. 
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Figure 9. Crystal structures of the vitamin D-binding protein. The illustration was produced 
by PyMol using the atomic coordinates from the Protein Data Bank, PDB1J78 [68]. 
 
2.5.1. 1,25-Dihydroxy-[26,27-3H]vitamin D3 
Vitamin D3 undergoes photoisomerisation to form suprasterol I, suprasterol II and 5,6-transvitamin 
D3 [69]. Link et al. reported that 25-OH-[26,27-
3H]vitamin D3 was capable of forming covalent bonds 
with human plasma proteins upon photoirradiation [70]. Underivatized 1,25-dihydroxy[26,27-3H]vitamin 
D3 was successfully used to photolabel the 1,25-dihydroxyvitamin D3 receptor upon ultraviolet 
irradiation at 220–280 nm [71,72]. 
2.5.2. 3-Deoxy-3-azido-25-hydroxyvitamin D3 
3-Deoxy-3-azido-25-hydroxyvitamin D3 (Az-25-OH-D3) is synthesized from tritiated 25-hydroxy-
vitamin D3 by the direct attachment of the photoactivatable azido substituent to the C-3 position, as  
C-3 does not seem to involve in ligand binding. Az-25-OH-D3 showed only a 20-fold reduction in 
binding affinity compared to the parent compound, and becomes covalently bound to VDBP upon 
photoirradiation with medium-intensity, short-wavelength (254-nm) UV light for 5 min or less. The 
covalent binding was inhibited by 70%–80% in the presence of 25-hydroxyvitamin D3, indicating the 
covalent binding took place at the vitamin D binding site of the protein. Four plasma proteins were 
photolabeled by Az-25-OH-D3 when photolabeling experiment was conducted using human plasma. 
VDBP was the only protein of the four that was unlabeled in the presence of 25-hydroxyvitamin D3 [70]. 
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2.5.3. 25-Hydroxy(26,27-3H)vitamin D3 -3β-3'-[N-(4-azido-2-nitrophenyl)amino]propyl Ether 
25-Hydroxyvitamin D3 3β-[N-(4-azido-2-nitrophenyl)glycinate] (25-OH-D3-ANG), a photoaffinity 
analogue of 25-OH-D3 was shown by Ray et al. to specifically bind to rat VDBP and to covalently 
label the protein on UV photoirradiation for 15 min [73]. However, the vulnerability of the ester  
bond in 3H-25 OH-D3-ANG in the strongly basic pH conditions during carboxymethylation of the 
photolabeled protein led to a complete loss of the radioactivity, impeding further identification of the 
labelling site. A hydrolytically stable photoaffinity analogue of 25-OH-D3, 25-hydroxyvitamin D3  
3β-3'-[N-(4-azido-2-nitrophenyl)amino]propylether (25-OH-D3-ANE) was developed. A 2 min UV 
irradiation was found to be effective in covalently labeled the rat VDBP [74]. The cyanogen bromide 
fragment of the photolabeled rat VDBP with a molecular weight of 11.5 kDa that represents the  
N-terminus through residue 108 of the intact protein was found to contain most of the covalently 
attached radioactivity [75]. The 25-OH-D(3)-binding pocket of the vitamin D-binding protein appears 
to be sterically restricted [76]. Further photolabeling experiments using photoaffinity analogues of  
25-hydroxyvitamin D3 with probes at the C-19 position that failed to specifically label VDBP shed 
light on the orientation of 25-OH-D3 in the binding pocket in which the C3-OH group at the A-ring 
points towards the binding cavity, while the C19-exocyclic methylene group projects outside the  
cavity [77,78]. 
2.6. α-Fetoprotein 
α-Fetoprotein (AFP) is thought to be the fetal counterpart of serum albumin. It is a major plasma 
protein during fetal life, but expression in adults is often associated with hepatoma or teratoma. α-
Fetoprotein exists in monomeric, dimeric and trimeric forms. It binds copper, nickel, fatty acids and 
bilirubin [79]. 
2.6.1. 16-Diazo[3H]estrone and 4-azido[3H]estradiol 
16-Diazo[3H]estrone has been shown to form a covalent attachment at the estrogen-binding site of 
rat AFP upon photoirradiation for 30 min at 300 nm. The photocovalent attachment appears to be 
predominated by pseudophotoaffinity labelling. On the other hand, 4-azido[3H]estradiol has been 
reported to undergo extensive photocovalent attachment to AFP but the attachment is nonspecific in 
nature [80]. 
2.7. Sex Hormone-Binding Globulin 
Sex hormone-binding globulin (SHBG) is a homodimeric plasma glycoprotein that participates in 
regulating steroid responses. (Figure 10) Human SHBG contains one O-linked and two N-linked 
oligosaccharides at Thr-7 and at Asn-351 and Asn-367, respectively, but the glycans do not seem to 
involve in steroid binding [81]. This protein has a high binding affinity for 17β-hydroxysteroid 
hormones such as testosterone and oestradiol. Plasma SHBG concentrations are affected by a number 
of different diseases as well as drugs, hence measuring SHBG levels can be useful in the evaluation of 
mild disorders and the identification of patients who are more likely to respond to therapy [82]. 
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Figure 10. Crystal structures of the human sex hormone-binding globulin. The illustration 
was produced by PyMol using the atomic coordinates from the Protein Data Bank, 
PDB1KDK [83]. 
 
2.7.1. [3H]Δ6-Testosterone ([1,2-3H]17β-hydroxy-4,6-androstadien-3-one) and Δ6-[17-3H] Estradiol 
[3H]Δ6-Testosterone can be used as a photolabeling agent due to fact that the unsaturated ketone in 
the molecule is photoexcitable at 345 nm [84,85]. Hydrogen abstraction via a long lived excited triplet 
state upon photoirradiation has been proposed to be the covalent bond formation mechanism for both 
Δ6-testosterone and Δ6-[3H]estradiol [86]. The methionine at position 139 of human SHBG interacts 
with the photoaffinity ligand, Δ6-testosterone [87,88]. Purified rabbit and sheep SHBGs photolabeled 
by unsubstituted delta 6-testosterone revealed that the photoattachment occurred exclusively at 
methionine-133 of rabbit SHBG, whereas the methionine-139 residue is the main site of photolabeling 
in sheep SHBG [81]. Human SHBG purified from late-pregnancy serum and labelled with [3H]delta  
6-testosterone, either by iodination (125I) or by photoaffinity were used to investigate the 
internalization of SHBG in the epididymis of the cynomologus monkey, Macaca fascicularis [89,90]. 
On the other hand, rat androgen-binding protein photolabelled with [3H]Δ6-testosterone has been used 
to study the binding of photolabelled ABP to plasma membranes of epithelial epididymal cells in rats [91]. 
In an attempt to further characterise the steroid binding site, Chambon et al. synthesized nine 
photoaffinity labelling reagents of 17α-alkylamine derivatives of 3β-androstanediol to conduct 
topological mapping. The study revealed that the conserved Trp-84, Pro-130 and Lys-134 residues are 
all located in the vicinity of the D ring of the steroid ligand binding site of human SHBG [92]. 
2.8. Corticosteroid-Binding Globulin 
Corticosteroid-binding globulin (CBG) is a member of the serine proteinase inhibitor (serpin) 
family that functions in the transport of glucocorticoids and progestins in the blood and regulates their 
access to target cells. (Figure 11) CBG is an α-globulin protein and a heavily glycosylated protein 
containing six N-linked glycans that are involved in the CBG-receptor interaction. Its steroid-binding 
site resembles the thyroxin-binding site in the related serpin, thyroxin-binding globulin [93–95]. 
Molecules 2013, 18 13847 
 
 
Figure 11. Crystal structures of the human corticosteroid-binding globulin. The illustration 
was produced by PyMol using the atomic coordinates from the Protein Data Bank, 
PDB2VDY [96]. 
 
2.8.1. 21-Diazo-21-[6,7-3H]deoxycorticosterone and Unsubstituted Tritiated Δ6-derivatives of Cortisol, 
Corticosterone, Progesterone and Testosterone 
21-Diazo-21-[6,7-3H]deoxycorticosterone was first synthesized as an analog of corticosterone of 
high specific activity, for photolabeling the high affinity steroid-binding human corticosteroid-binding 
globulin. Irradiation of CBG with the 21-diazo derivative resulted in irreversible binding to the  
protein [97]. A later attempt in specific covalent labelling of purified human CBG by 2-fold molar 
excess of unsubstituted Δ6-[3H]cortisol, Δ6-[3H] corticosterone, and Δ6-[3H]progesterone after 30 min 
irradiation at >300 nm produced a labelling efficiency of 0.21, 0.14, and 0.08 mol of label/mol of CBG 
respectively. The most plausible mechanism of photolabeling was preferential hydrogen abstraction by 
excited triplet radicals derived from the dienone moiety in these three compounds. Trp-371 was 
concluded to be the main site of specific covalent bond formation with the three steroids [98]. On the 
other hand, [3H]Δ6-testosterone has been shown to also form specific covalent binding with hamster 
serum CBG, in addition to human SHBG [99]. 
3. Conclusions 
The advantages of using a natural ligand with a photoreactive group as a photolabeling agent 
include avoiding laborious chemical synthesis and the subsequent determination of the binding affinity 
of the derivatised photolabeling agent. The great advantage of using underivatized natural ligands for 
photoaffinity labeling lies not only in the fact that they are easily availabile but also because  
non-specific covalent binding is typically minimal, since the binding specificity of the natural 
photolabile ligand remains constant. This is especially important when the identification of binding 
protein in plasma that contains an abundance of different types of proteins might by chance interact 
with the derivatised photolabeling agent with a high affinity. Table 1 lists examples of natural ligands 
with a photoreactive moiety that could potentially be used to photolabel proteins.  
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Table 1. Natural ligands with photolabile moieties. 




wavelengths (nm) and time
Target protein Reference 
[14C]Halotane 254 (10 s) Albumin [23] 
[3H8]Leukotriene E4 300 (4 min) Albumin, glutathione transferases [28] 
[14C]Ketoprofen 310 (30 min) HSA [11] 
[3H]Flunitrazepam 310 (30 min) HSA, AGP, benzodiazepine receptor [22,38] 
[3H]7-Hydroxystaurosporine (UCN-01) 310 (30 min) AGP [41] 
[3H]Glibenclamide 254 (3 min) 
140 kDa sulfonylurea receptor in the 
rat beta-cell membrane and albumin 
[100] 
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Table 1. Cont. 




wavelengths (nm) and time
Target protein Reference 
[3H]Benzylpenicillin 
 
254 (2 min) 
127 kDa brush border membrane 
protein from rabbit small intestine and 
albumin 
[101] 
[3',5'-125I]Thyroxine ([125I]T4),  
[3'-125I]Triiodothyronine 
>300 (80 s) 
Human thyroxine binding globulin 
and bovine serum albumin 
[47] 
All-trans-[11,12-3H]Retinoic acid 365 (15 min) 
Cellular retinoic acid-binding protein 
and albumin 
[56] 
[14C]Doxorubicin >254 (5 min) Junctional sarcoplasmic reticulum [102] 
[3H]Taxol 254 (30 min) Tubulin [103] 
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Table 1. Cont. 




wavelengths (nm) and time
Target protein Reference 
[5-3H]Dolastatin 10 254nm (10 min) Beta-tubulin [104] 
[3H]Colchicine >305 (5 min) Tubulin [105] 
[3H]Vinblastine >310 (7 min) Tubulin [104] 
[3H]Forskolin 254 (30 s) Erythrocyte D-glucose transporter [106] 
[3H]Cytochalasin B 254 (30 s) 
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Table 1. Cont. 




wavelengths (nm) and time
Target protein Reference 
[3H]Nitrendipine 254 (20 s) 32 kDa cardiac membrane protein [108] 
[3H]Bumetanide 
Flash lights (2 min) 
300–400 (10 min) 
Na+-K+-Cl− cotransporter [109,110] 
[3H]Clonazepam Shortwave UV (60 min) 
Central type of benzodiazepine 
receptor 
[111] 
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In addition, the identification of the binding proteins in plasma would assist in the accurate 
characterization of the pharmacokinetic profiles of drugs [17,112]. Emerging new high-throughput 
analytical technologies would undoubtedly extend the potential of photoaffinity labeling to become a 
rapid with high sensitivity and robust means for target protein identification [1]. 
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